Aytu BioPharma to Report Third Quarter Fiscal 2024 Financial and Operational Results on May 15, 2024
Aytu BioPharma to Report Third Quarter Fiscal 2024 Financial and Operational Results on May 15, 2024
DENVER, CO / ACCESSWIRE / May 8, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its financial and operational results for its third quarter of fiscal 2024 for the period ended March 31, 2024, after the market close on Wednesday, May 15, 2024. The Company has scheduled a conference call and webcast that same day, Wednesday, May 15, 2024, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.
丹佛，科羅拉多州/ACCESSWIRE/2024年5月8日/Aytu BioPharma，Inc.（“公司”或“Aytu”）（NASDAQ：AYTU），一家致力於商業化新型治療藥物的製藥公司，將於2024年5月15日星期三市場收盤後公佈截至2024年3月31日的財務和業務業績。該公司已安排在同一天，即2024年5月15日星期三下午4:30（美國東部時間）召開電話會議和網絡播放，對業績進行評估，並進行問答環節。
Conference Call Details
電話會議詳情
Date and Time: Wednesday, May 15, 2024, at 4:30 p.m. Eastern Time
日期和時間：2024年5月15日星期三美國東部時間下午4:30。
Call-in Information: Interested parties can access the conference call by dialing (888) 506-0062 for U.S. callers or +1 (973) 528-0011 for international callers and using the participant access code 300411.
呼叫信息：有興趣的各方可以撥打（888）506-0062（美國呼叫者）或+1（973）528-0011（國際呼叫者），並使用參與者訪問代碼300411進入電話會議。
Webcast Information: The webcast will be accessible live and archived at and accessible on the Investors section of the Company's website at under Events & Presentations.
網絡廣播信息：網絡廣播將在直播時和歸檔時在Aytu公司網站的投資者部分下可用。請參見“事件和介紹”下的信息。
Replay: A teleconference replay of the call will be available until May 29, 2024 at (877) 481-4010 for U.S. callers or +1 (919) 882-2331 for international callers and using replay access code 50379.
重播：會議通話的重播將於2024年5月29日之前可通過撥打（877）481-4010（美國呼叫者）或+1（919）882-2331（國際呼叫者），並使用重播訪問代碼50379來訪問。
About Aytu BioPharma, Inc.
關於Aytu BioPharma，Inc。
Aytu is a pharmaceutical company focused on commercializing novel therapeutics. The Company's prescription products include Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), Karbinal ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. To learn more, please visit aytubio.com.
Aytu是一家專注於商業化新型治療藥物的製藥公司。該公司的處方產品包括Adzenys XR-ODT（苯丙胺）長效口腔崩解片（包括加粗警告的完整處方信息）和Cotempla XR-ODT（哌甲酯）長效口腔崩解片（包括加粗警告的完整處方信息）用於治療注意力缺陷多動障礙（ADHD），Karbinal ER（卡比諾克唑男ate），一種擴釋抗組胺懸液，用於治療多種過敏性疾病，以及兩種補充氟化物的處方維生素產品線Poly-Vi-Flor和Tri-Vi-Flor，適用於嬰兒和兒童的各種配方。欲了解更多信息，請訪問aytubio.com。
Contacts for Investors:
投資者聯繫人：
Mark Oki, Chief Financial Officer
Aytu BioPharma, Inc.
moki@aytubio.com
Mark Oki，致富金融首席財務官
Aytu BioPharma，Inc。
moki@aytubio.com
Robert Blum or Roger Weiss
Lytham Partners
aytu@lythampartners.com
Robert Blum或Roger Weiss
Lytham Partners
aytu@lythampartners.com
SOURCE: Aytu BioPharma, Inc.
來源：Aytu BioPharma，Inc。
譯文內容由第三人軟體翻譯。